Latest On Actinium Pharmaceuticals, Inc (ATNM):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-10 19:22 EST | News | Actinium: Highly Derisked Late Stage Molecule With Successful Trial | N/A |  |
| 2023-04-03 17:49 EST | News | Actinium Pharmaceuticals reports FY results | N/A | |
| 2023-02-21 08:02 EST | News | Actinium jumps 13% as late-stage trial for leukemia candidate meets main goal | N/A | |
| 2023-01-19 16:14 EST | News | Actinium Pharmaceuticals: Moving Towards FDA Approval | N/A | |
| 2023-01-10 20:02 EST | News | Actinium Pharmaceuticals: Prep For February | N/A | |
| 2022-11-22 16:26 EST | News | Actinium sheds 15% after shareholder letter | N/A | |
| 2022-11-02 13:46 EST | News | Actinium hits over two-year high as Novartis executive joins to lead Iomab-B sales | N/A | |
| 2022-10-31 14:40 EST | News | Actinium climbs 23% as lead asset meets main goal in Phase 3 leukemia trial | N/A | |
| 2022-10-28 12:48 EST | News | Actinium: Overview Of A Promising Innovator | N/A | |
| 2022-10-18 02:06 EST | News | Actinium: 2 Catalysts Before End Of 2022 Could Boost Value | N/A | |
| 2022-10-03 22:51 EST | News | Cantor lists three “high conviction” Phase 3 biotech readouts for Q4 | N/A | |
| 2022-08-26 01:22 EST | News | Actinium started at buy at B Riley on bone marrow transplant conditioning therapy | N/A | |
| 2022-04-14 05:03 EST | News | Actinium maintained at outperform at William Blair following Immedica Pharma deal | N/A | |
| 2022-04-13 14:20 EST | News | Actinium Pharmaceuticals (ATNM) Investor Presentation - Slideshow | N/A | |
| 2022-04-12 08:38 EST | News | Actinium gains on agreement with Immedica Pharma for conditioning agent | N/A | |
| 2022-03-12 02:29 EST | News | Actinium: Promises, Promises | N/A | |
| 2022-02-07 18:10 EST | News | Actinium Pharmaceuticals, Inc. (ATNM) Investor Presentation - Slideshow | N/A | |
| 2022-01-05 17:33 EST | News | Actinium Pharma collaborates with EpicentRx to develop therapy for acute myeloid leukemia | N/A | |
| 2021-12-16 23:03 EST | News | Actinium: SIERRA Is Progressing Well Towards Final Data Readout | N/A | |
| 2021-11-05 01:29 EST | News | Actinium completes enrollment in Phase 1 Actimab-A leukemia trial | N/A | |
| 2021-09-17 13:59 EST | News | Actinium completes enrollment in pivotal Iomab-B leukemia study | N/A | |
| 2021-07-20 19:43 EST | News | Actinium Pharmaceuticals added to Russell Microcap Index | N/A | |
| 2021-07-20 19:27 EST | News | Actinium: A Story Of Delays And Promises, About To Come To Fruition | N/A | |
| 2021-03-24 14:30 EST | News | Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy | N/A | |
| 2021-03-05 15:14 EST | News | The Verdict On Actinium Pharmaceuticals | N/A | |
| 2021-01-13 10:37 EST | News | Actinium, Astellas in research pact for radiotherapies | N/A | |
| 2021-01-02 15:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-29 13:13 EST | News | Actinium down 22% on independent data monitoring committee recommendation for Iomab-B trial | N/A | |
| 2020-12-13 03:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-08 20:21 EST | News | Actinium Pharmaceuticals rises 2% after seeing 67% ORR in first cohort in Actimab-A/venetoclax combination trial | N/A | |
| 2020-12-07 22:22 EST | News | Actinium's Iomab-B shows encouraging action in late-stage leukemia study | N/A | |
| 2020-12-06 16:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 23:01 EST | News | Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results | N/A | |
| 2020-11-15 11:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 03:11 EST | Analyst Rating | The Analyst Target Price has decreased from $43.33 to $38.75. | Neutral | |
| 2020-11-02 16:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 17:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-30 12:14 EST | Earnings Estimate | An EPS average of -$0.51 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-10-21 15:47 EST | News | Actinium Pharma cheers National Institutes of Health grant to study novel Iomab-ACT | N/A | |
| 2020-10-15 10:47 EST | News | Actinium Pharmaceuticals expands R&D capabilities with new research facility in New York City | N/A | |
| 2020-09-26 04:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 06:01 EST | News | Actinium concludes dosing cohort in Phase 1 Actimab-A/venetoclax combination trial | N/A | |
| 2020-09-23 16:13 EST | Analyst Rating | The Analyst Target Price has decreased from $70 to $43.33. | Neutral | |
| 2020-09-22 22:59 EST | News | Actinium Pharmaceuticals: Far Enough Along For A Small Bet | N/A | |
| 2020-09-15 08:02 EST | News | Actinium concludes planned Phase 1 Actimab-A CLAG-M combination trial | N/A | |
| 2020-09-04 04:09 EST | Analyst Rating | The Analyst Target Price has decreased from $76.67 to $70. | Neutral | |
| 2020-08-18 12:10 EST | Analyst Rating | The Analyst Target Price has decreased from $82.5 to $76.67. | Neutral | |
| 2020-08-16 12:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 12:10 EST | Analyst Rating | The Analyst Target Price has increased from $2.75 to $82.5. | Buy | |
| 2020-08-12 04:11 EST | Stock Split | A stock split has occured on Aug 11, 2020 with a split factor of 1:30. | Neutral | |
About Actinium Pharmaceuticals, Inc (ATNM):
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
General
- Name Actinium Pharmaceuticals, Inc
- Symbol ATNM
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:30
- Last Split Date2020-08-11
- Fiscal Year EndDecember
- IPO Date2012-12-27
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.actiniumpharma.com
View More
Valuation
- Price/Book (Most Recent Quarter) 2.7
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.48
- Return on Assets -39%
- Return on Equity -74%
- Earnings Per Share -$0.19
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 121.74 million
- EBITDA -23111352
- Analyst Target Price $38.75
- Book Value Per Share $3.34
View More
Share Statistics
- Shares Outstanding 13.59 million
- Shares Float 13.25 million
- % Held by Insiders 155%
- % Held by Institutions 22.05%
- Shares Short 803265
- Shares Short Prior Month 806693
- Short Ratio 1.75
- Short % of Float 6%
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 1.07
- 52 Week High $19.47
- 52 Week Low $4.71
- 50 Day Moving Average 8.63
- 200 Day Moving Average 9.66
View More
Dividends
- Dividend Date 2020-08-11
- ExDividend Date N/A
- Dividend Yield 0%
View More
Actinium Pharmaceuticals, Inc (ATNM) Dividend Calendar:
ATNM's last dividend payment was made to shareholders on August 11, 2020.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Actinium Pharmaceuticals, Inc (ATNM) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-10-23 | $N/A | -$0.36 | -$0.42 | 13.25% |
| 2020-06-30 | 2020-08-14 | $N/A | -$0.41 | -$0.45 | 8.89% |
| 2020-03-31 | 2020-05-08 | $N/A | -$0.90 | -$1.20 | 25% |
| 2019-12-31 | 2020-03-13 | $N/A | -$0.90 | -$1.20 | 25% |
| 2019-09-30 | 2019-11-12 | $N/A | -$1.20 | -$1.20 | 0% |
| 2019-06-30 | 2019-08-09 | $N/A | -$0.90 | -$1.20 | 25% |
| 2019-03-31 | 2019-05-10 | $N/A | -$1.50 | -$1.80 | 16.67% |
| 2018-12-31 | 2019-03-15 | $N/A | -$1.50 | -$1.60 | 6.25% |
| 2018-09-30 | 2018-11-09 | $N/A | -$1.80 | -$1.30 | -38.46% |
| 2018-06-30 | 2018-08-09 | $N/A | -$1.20 | -$1.90 | 36.84% |
| 2018-03-31 | 2018-05-10 | $N/A | -$2.10 | -$1.80 | -16.67% |
| 2017-12-31 | 2018-03-16 | $N/A | -$1.80 | -$2.85 | 36.84% |
| 2017-09-30 | 2017-11-03 | $N/A | -$2.70 | -$2.70 | 0% |
| 2017-06-30 | 2017-08-04 | $N/A | -$3.60 | -$0.13 | -2669.23% |
| 2017-03-31 | 2017-05-15 | $N/A | -$4.20 | -$3.90 | -7.69% |
| 2016-12-31 | 2017-03-16 | $N/A | -$3.60 | -$4.20 | 14.29% |
| 2016-09-30 | 2016-10-28 | $N/A | -$4.20 | -$4.95 | 15.15% |
| 2016-06-30 | 2016-07-29 | $N/A | -$4.50 | -$4.35 | -3.45% |
| 2016-03-31 | 2016-05-10 | $N/A | -$3.00 | -$4.80 | 37.5% |
| 2015-12-31 | 2016-03-11 | $N/A | -$4.80 | -$3.50 | -37.14% |
| 2015-09-30 | 2015-10-30 | $N/A | -$0.10 | -$0.18 | 44.44% |
| 2015-06-30 | 2015-08-07 | $N/A | -$0.20 | -$0.19 | -5.26% |
| 2015-03-31 | 2015-05-08 | $N/A | -$0.09 | -$0.20 | 55% |
| 2014-12-31 | 2015-03-17 | $N/A | -$0.17 | -$0.19 | 10.53% |
| 2014-09-30 | 2014-10-31 | $N/A | -$0.21 | -$0.14 | -50% |
| 2014-06-30 | 2014-08-12 | $N/A | $0.10 | -$0.13 | 176.92% |
| 2014-03-31 | 2014-05-12 | $N/A | -$0.66 | -$0.08 | -725% |
| 2013-12-31 | 2014-02-28 | $N/A | -$0.25 | -$0.07 | -257.14% |
| 2013-09-30 | 2013-11-14 | $N/A | -$0.06 | -$0.08 | 25% |
| 2013-06-30 | 2013-08-28 | $N/A | -$3.77 | ||
| 2013-03-31 | 2013-05-29 | $N/A | -$0.97 | ||
| 2012-12-31 | 2012-12-31 | $N/A | -$227.10 | ||
| 2012-09-30 | 2012-09-30 | $N/A | -$0.01 | ||
| 2012-06-30 | 2012-06-30 | $N/A | -$0.02 | ||
| 2012-03-31 | 2012-03-31 | $N/A | -$0.03 | ||
| 2011-12-31 | 2011-12-31 | -$0.01 | |||
| 2011-09-30 | 2011-09-30 | -$0.01 | |||
| 2011-06-30 | 2011-06-30 | $0.06 |
Actinium Pharmaceuticals, Inc (ATNM) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Actinium Pharmaceuticals, Inc (ATNM) Chart:
Actinium Pharmaceuticals, Inc (ATNM) News:
Below you will find a list of latest news for Actinium Pharmaceuticals, Inc (ATNM) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Actinium Pharmaceuticals, Inc (ATNM) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | 2.5 | 0.05 | CALL | 0 | 786 | 263.53 | FALSE | 0 | 0 |
| 2025-05-16 | 5 | 0.04 | CALL | 0 | 271 | 468.21 | FALSE | 0 | 0 |
| 2025-05-16 | 7.5 | 0.05 | CALL | 0 | 203 | 1279.81 | FALSE | 0 | 0 |
| 2025-05-16 | 2.5 | 1.05 | PUT | 0 | 11 | 1155.64 | TRUE | 0 | 0 |
| 2025-05-16 | 5 | 4.3 | PUT | 0 | 13 | 922.26 | TRUE | 0 | 0 |
| 2025-05-16 | 7.5 | 0 | PUT | 0 | 0 | 1143.61 | TRUE | 0 | 0 |
| 2025-06-20 | 2.5 | 0.07 | CALL | 0 | 41 | 171.02 | FALSE | 0 | 0 |
| 2025-06-20 | 5 | 0 | CALL | 0 | 0 | 835.99 | FALSE | 0 | 0 |
| 2025-06-20 | 7.5 | 0.05 | CALL | 0 | 4 | 551.47 | FALSE | 0 | 0 |
| 2025-06-20 | 2.5 | 0 | PUT | 0 | 0 | 730.64 | TRUE | 0 | 0 |
| 2025-06-20 | 5 | 3.57 | PUT | 0 | 0 | 494.96 | TRUE | 0 | 0 |
| 2025-06-20 | 7.5 | 6.1 | PUT | 0 | 1 | 503.48 | TRUE | 0 | 0 |
| 2025-08-15 | 2.5 | 0.15 | CALL | 1 | 241 | 131.54 | FALSE | 0 | 0 |
| 2025-08-15 | 5 | 0.05 | CALL | 0 | 292 | 167.05 | FALSE | 0 | 0 |
| 2025-08-15 | 7.5 | 0.05 | CALL | 0 | 55 | 680.82 | FALSE | 0 | 0 |
| 2025-08-15 | 2.5 | 1.4 | PUT | 0 | 24 | 150.61 | TRUE | 0 | 0 |
| 2025-08-15 | 5 | 0 | PUT | 0 | 0 | 209.1 | TRUE | 0 | 0 |
| 2025-08-15 | 7.5 | 5.8 | PUT | 0 | 0 | 550.15 | TRUE | 0 | 0 |
| 2025-11-21 | 2.5 | 0.6 | CALL | 1 | 290 | 123.48 | FALSE | 0.6 | 0 |
| 2025-11-21 | 5 | 0.1 | CALL | 3 | 257 | 126.84 | FALSE | 0.1 | 0 |
| 2025-11-21 | 7.5 | 0.05 | CALL | 40 | 211 | 129.72 | FALSE | 0.05 | 0 |
| 2025-11-21 | 2.5 | 1.35 | PUT | 0 | 19 | 171.35 | TRUE | 0 | 0 |
| 2025-11-21 | 5 | 0 | PUT | 0 | 0 | 140.54 | TRUE | 0 | 0 |
| 2025-11-21 | 7.5 | 0 | PUT | 0 | 0 | 151.35 | TRUE | 0 | 0 |
Latest ATNM Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:48 PM EST | 100 | $4.77 |
| Jun 13, 2022 7:56 PM EST | 100 | $4.79 |
| Jun 13, 2022 7:57 PM EST | 100 | $4.78 |
| Jun 13, 2022 7:58 PM EST | 67 | $4.79 |
| Jun 13, 2022 7:59 PM EST | 99 | $4.79 |
Actinium Pharmaceuticals, Inc (ATNM) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020016168/0001213900-20-016168-index.htm |
| 2020-08-13 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1388320/000000000020007425/0000000000-20-007425-index.htm |
| 2019-10-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000092189519002633/0000921895-19-002633-index.htm |
| 2020-04-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000092189520001200/0000921895-20-001200-index.htm |
| 2020-08-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000092189520002152/0000921895-20-002152-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000119380520000221/0001193805-20-000221-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019002982/0001213900-19-002982-index.htm |
| 2019-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019003738/0001213900-19-003738-index.htm |
| 2019-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390019003990/0001213900-19-003990-index.htm |
| 2019-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/0001213900-19-004269-index.htm |
| 2019-04-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390019006578/0001213900-19-006578-index.htm |
| 2019-04-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390019006717/0001213900-19-006717-index.htm |
| 2019-04-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390019006723/0001213900-19-006723-index.htm |
| 2019-05-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1388320/000121390019008289/0001213900-19-008289-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390019008291/0001213900-19-008291-index.htm |
| 2019-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390019010336/0001213900-19-010336-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012869/0001213900-19-012869-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012871/0001213900-19-012871-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012873/0001213900-19-012873-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012875/0001213900-19-012875-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012879/0001213900-19-012879-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012881/0001213900-19-012881-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012884/0001213900-19-012884-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012888/0001213900-19-012888-index.htm |
| 2019-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390019012891/0001213900-19-012891-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390019015171/0001213900-19-015171-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390019022937/0001213900-19-022937-index.htm |
| 2019-11-15 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1388320/000121390019023769/0001213900-19-023769-index.htm |
| 2019-11-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390019024626/0001213900-19-024626-index.htm |
| 2019-11-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1388320/000121390019024628/0001213900-19-024628-index.htm |
| 2019-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390019025210/0001213900-19-025210-index.htm |
| 2019-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390019026593/0001213900-19-026593-index.htm |
| 2020-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020007702/0001213900-20-007702-index.htm |
| 2020-04-21 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020009696/0001213900-20-009696-index.htm |
| 2020-04-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020009853/0001213900-20-009853-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020010060/0001213900-20-010060-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020011048/0001213900-20-011048-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/0001213900-20-011052-index.htm |
| 2020-05-08 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/0001213900-20-011475-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020012670/0001213900-20-012670-index.htm |
| 2020-06-16 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015102/0001213900-20-015102-index.htm |
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/0001213900-20-015104-index.htm |
| 2020-06-16 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015110/0001213900-20-015110-index.htm |
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015114/0001213900-20-015114-index.htm |
| 2020-06-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015266/0001213900-20-015266-index.htm |
| 2020-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/0001213900-20-015271-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020015376/0001213900-20-015376-index.htm |
| 2020-06-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020016168/0001213900-20-016168-index.htm |
| 2020-07-13 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020017370/0001213900-20-017370-index.htm |
| 2020-07-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020018562/0001213900-20-018562-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020020390/0001213900-20-020390-index.htm |
| 2020-08-07 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1388320/000121390020020895/0001213900-20-020895-index.htm |
| 2020-08-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022138/0001213900-20-022138-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022313/0001213900-20-022313-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022314/0001213900-20-022314-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022319/0001213900-20-022319-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022320/0001213900-20-022320-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/0001213900-20-022322-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/0001213900-20-022334-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022337/0001213900-20-022337-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022339/0001213900-20-022339-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022341/0001213900-20-022341-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1388320/000121390020022342/0001213900-20-022342-index.htm |
| 2020-10-07 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1388320/000121390020030519/0001213900-20-030519-index.htm |
| 2020-10-07 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1388320/000121390020030520/0001213900-20-030520-index.htm |
| 2020-10-23 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1388320/000121390020033053/0001213900-20-033053-index.htm |
| 2020-10-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1388320/000121390020033692/0001213900-20-033692-index.htm |
| 2020-10-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1388320/000121390020033693/0001213900-20-033693-index.htm |
| 2019-04-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000153561019000080/0001535610-19-000080-index.htm |
| 2020-01-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000153561020000018/0001535610-20-000018-index.htm |
| 2020-05-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1388320/000153561020000091/0001535610-20-000091-index.htm |
| 2020-08-14 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1388320/999999999520002161/9999999995-20-002161-index.htm |